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Edited by Francesc PosasAbstract The MAP kinase pathway inhibitor U0126 caused
phosphorylation and activation of AMP-activated protein kinase
(AMPK) and increased phosphorylation of its downstream tar-
get acetyl-CoA carboxylase, in HEK293 cells. This eﬀect only
occurred in cells expressing the upstream kinase, LKB1. Of
two other widely used MAP kinase pathway inhibitors not clo-
sely related in structure to U0126, PD98059 also activated
AMPK but PD184352 did not. U0126 and PD98059, but not
PD184352, also increased the cellular ADP:ATP and AM-
P:ATP ratios, accounting for their ability to activate AMPK.
These results suggest the need for caution in interpreting exper-
iments conducted using U0126 and PD98059.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The MAP kinase (ERK) cascade represents one of the
major signalling pathways by which cells respond to growth
factors that stimulate cell growth and proliferation. Two
experimental tools that have been very widely used in the
study of this pathway are pharmacological inhibitors, i.e.,
PD98059 [1] and U0126 [2]. Since the ﬁrst reports in 1995
and 1998, respectively, more than 4000 papers in PubMed
have reported the use of PD98059 and more than 1200 pa-
pers the use of U0126. More recently, a newer inhibitor has
been found, i.e., PD184352 [3]. All three inhibitors work by
blocking activation of MKK1/MEK1 by upstream kinases,
such as Raf-1, which occurs at much lower concentrations
than inhibition of MKK1/MEK1 activity [4,5]. In a screen
of their eﬀects on a range of 24 diﬀerent protein kinases,
these inhibitors appeared to be rather selective for MKK1/
MEK1, although PD184352 was the most potent and selec-
tive [5].
The AMP-activated protein kinase (AMPK) is a protein ki-
nase that is switched on by a fall in cellular energy status viaAbbreviations: ACC, acetyl-CoA carboxylase; AMPK, AMP-activated
protein kinase
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nase domain [6,7]. Phosphorylation of Thr-172 is catalysed
by an upstream kinase that is a complex between the tumour
suppressor, LKB1 and two accessory subunits, STRAD and
MO25 [8,9]. This cascade is activated in a sensitive manner
by a rise in the cellular AMP:ATP ratio [10], with AMP and
ATP binding in a mutually exclusive manner to the CBS do-
mains in the AMPK c subunit [11,12]. Once activated, AMPK
switches on ATP-producing catabolic pathways while switch-
ing oﬀ ATP-consuming processes such as lipid biosynthesis
[6,7].
During the course of studies in which we were investigat-
ing possible interactions between the MAP kinase and
AMPK signalling pathways, we made the surprising obser-
vation that the inhibitor U0126 caused a marked activation
of AMPK in human embryonic kidney 293 (HEK293) cells.
In this report, we show that this eﬀect is also observed with
PD98059, but not PD184352, and that it is due to the fact
that U0126 and PD98059 increase the cellular AMP:ATP
ratio when used at concentrations that are typically used
in the literature. This sounds a note of caution in the use
of these compounds to study the actions of the MAP kinase
pathway.2. Methods
U0126 and PD98058 were from Cell Signalling Technology and
PD184352 was a gift from Philip Cohen, Dundee. HEK293 cells were
maintained in Dulbeccos modiﬁcation of Eagles medium (low glu-
cose) plus 10% foetal bovine serum. HeLa cells stably expressing wild
type or kinase-dead LKB1 have been described [8]. AMPK activity was
determined by immunoprecipitate kinase assays using anti-AMPK-a1
and -a2 antibodies [13]. Antibodies recognising AMPK phosphory-
lated on Thr-172 (anti-pT172) [14], AMPK-a1 and -a2 [15] and
acetyl-CoA carboxylase-1 (ACC1) phosphorylated on Ser-80 [16] were
described previously. Quantiﬁcation of ratios of signals from phos-
phorylated and total protein using these antibodies was performed
by dual labelling using the LI-COR Odyssey IR imager as described
[8]. Antibodies against the phosphorylated, active forms of p42
(Erk2) and p44 (Erk1) were from Cell Signalling Technology. Contents
of ATP and ADP were determined for cells in 6 cm culture dishes by
quickly pouring oﬀ the medium, adding 350 ll of ice-cold 5% per-
chloric acid, scraping the cells oﬀ with a plastic scraper, and centrifug-
ing (14 000 · g; 3 min, 4 C) to remove insoluble material. The
perchloric acid was then extracted from the supernatant and nucleo-
tides analysed by capillary electrophoresis of perchloric acid extracts
as described previously [17].
All incubations of cells were performed in triplicate and results are
expressed as means ± S.E.M.ation of European Biochemical Societies.
Fig. 1. Eﬀects of diﬀerent concentrations of U0126 on: (A) the activity
and phosphorylation (Thr-172) of AMPK, and phosphorylation (Ser-
80) of ACC1; and (B) phosphorylation of p44 and p42 (Erk1/Erk2) in
HEK293 cells (15-min incubations). Results for phosphorylation of
AMPK and ACC1 were obtained as ratios of the signals obtained
using a phosphospeciﬁc antibody and a phosphorylation-independent
probe for the same protein. All results are expressed relative to the
value obtained in controls lacking U0126. The basal activity of AMPK
in the HEK-293 cells was 89 ± 3 pmol/min/mg of total lysate protein
Data in A were ﬁtted to the equation stimulation ¼ 1þ ððmaxima
stimulation basalÞ  ½drugnÞ  ðAn0:5 þ ½drugnÞ using GraphPadP-
rism 3.0 (GraphPad Software). The continuous lines are theoretica
curves drawn using the best-ﬁt parameters.
Fig. 2. Eﬀects of U0126 (20 lM), phenformin (10 mM) or both
compounds together, on AMPK activity in HeLa cells stably express-
ing wild type or kinase-dead (D194A mutant) LKB1 [8]. A concen-
tration of 10 mM is maximal for the eﬀect of phenformin on AMPK
activity (not shown).
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l3. Results
3.1. U0126 activates AMPK in HEK293 cells
Fig. 1A shows that in HEK293 cells, U0126 caused a 5-
fold activation of AMPK that was maximal at about 80
lM with a half-maximal eﬀect at 15 lM. Phosphorylation
of AMPK and its downstream target, ACC, were assessed
by probing blots simultaneously using phosphospeciﬁc anti-
bodies and phosphorylation-independent probes (anti-a1, -a2
antibodies in the case of AMPK, streptavidin in the case of
ACC). The antibodies or other probes were directly conjugated
with ﬂuorescent dyes absorbing in diﬀerent regions of the in-
fra-red spectrum, and ﬂuorescence was measured simulta-
neously in two channels on an infra-red scanner. The results
are expressed as a ratio, which provides an accurate measure
of phosphorylation status that automatically corrects for any
variations in protein loading. This showed that activation of
AMPK was associated with an increase in phosphorylation
of the activating site on AMPK and of a key target of AMPK,
ACC, at the inactivating site, in both cases with half-maximal
eﬀects at 15 lM. Separate blots using isoform-speciﬁc antibod-
ies (not shown) showed that these cells express exclusively the
ACC-1 (-a) isoform of ACC, where the AMPK site in humans
is at Ser-80. A time course (not shown) revealed that activation
and phosphorylation of AMPK, and the phosphorylation of
Ser-80 on ACC-1 reached a maximum after around 10–20 min.
As expected, U0126 also inhibited the phosphorylation of
the p44/p42 (Erk1/Erk2) isoforms of MAP kinase. However,
the half-maximal eﬀect (I0.5) on MAP kinase phosphorylation
occurred at about 1 lM (Fig. 1B), i.e., 10-fold lower than theA0.5 for the eﬀects on AMPK. A time course revealed that the
inhibition of p44/p42 phosphorylation was maximal at about
20 min (not shown).
3.2. Activation of AMPK by U0126 requires the upstream
kinase, LKB1
Since U0126 caused increased phosphorylation of the acti-
vating phosphorylation site on AMPK, Thr-172, we ex-
pected that it would require the presence of the upstream
kinase, LKB1. To test this, we made use of the fact that
HeLa cells do not express LKB1, but that derivatives of
HeLa cells stably expressing either wild type or kinase-inac-
tive LKB1 (D194A mutant) [18] were available to us. Fig. 2
shows that in HeLa cells expressing wild type LKB1, both
U0126 and the anti-diabetic drug phenformin activated
AMPK, but that in cells expressing kinase-inactive LKB1,
the basal AMPK activity was very low and neither agent
caused signiﬁcant activation. Fig. 2 also shows that the ef-
fects of U0126 and phenformin were not additive, indicating
that they might be occurring via a common mechanism. The
concentration of U0126 used in this experiment (20 lM) is
slightly sub-maximal but was chosen because it is typical
of concentrations used to inhibit the MAP kinase pathway
in the literature.
3.3. AMPK is also activated by PD98095 but not by PD184352
The discrepancy between the concentrations of U0126 that
gave half-maximal eﬀects on AMPK activation and p44/p42
phosphorylation suggested that the agent might be acting on
the two pathways via diﬀerent mechanisms. To address this,
we studied two other inhibitors of MKK1/MEK1 activation,
i.e., PD98095 and PD184352. PD98059 also activated
AMPK and this was associated with increased phosphoryla-
tion of Thr-172 on AMPK and Ser-80 on ACC-1. However,
once again there was a small discrepancy between the con-
centrations of PD98059 that aﬀected those parameters and
those that inhibited p42/p44 phosphorylation. Maximal ef-
fects on phosphorylation and activation of AMPK, and
phosphorylation of ACC-1 occurred at 100 lM with half-
maximal eﬀects at 35 lM, whereas inhibition of p44/p42
phosphorylation appeared to be almost maximal at 25 lM
(Fig. 3).
Fig. 3. (A,B) eﬀects of increasing concentrations of PD98059 and PD184352 (60-min incubation) on the activity and phosphorylation (Thr-172) of
AMPK and the phosphorylation (Ser-80) of ACC1. (C,D) Eﬀects of diﬀerent concentrations of PD98059 and PD184532 on the phosphorylation of
p44 and p42 (Erk1/Erk2) in HEK-293 cells. The basal activity of AMPK in these experiments was 31 ± 4 pmol/min/mg of total lysate protein. Data in
(A) were ﬁtted to the same equation as for Fig. 1A, and the continuous lines are theoretical curves drawn using the best-ﬁt parameters.
Phosphorylation of AMPK was also determined in (B), but did not change and is not shown.
238 K. Dokladda et al. / FEBS Letters 579 (2005) 236–240In complete contrast, PD184352 produced a dramatic inhibi-
tion of p44/p42 phosphorylation at the lowest concentration
used (0.5 lM, Fig. 3D), but did not produce any signiﬁcant
activation or phosphorylation of AMPK, or phosphorylation
of ACC-1, at concentrations up to 4 lM (Fig. 3B).
3.4. U0126 and PD98059, but not PD184352, cause an increase
in cellular ADP:ATP and AMP:ATP ratios
Fig. 4 shows that U0126 and PD98059, at 20 and 50 lM,
respectively, (typical of concentrations used in the literature),
caused a 2-fold increase in the cellular ADP:ATP ratio and a
somewhat larger increase in the AMP:ADP ratio. By contrast,Fig. 4. Eﬀect of incubation with 20 lM U0126 (20 min), 50 lM
PD98059 (20 min) or 1 lM PD184352 (60 min) on the cellular
ADP:ATP and AMP:ATP ratios. Results are expressed relative to the
value obtained in controls lacking inhibitors. The ATP:ADP and
ATP:AMP ratios in control cells were 8.4 ± 0.2 and 102 ± 7,
respectively.PD184352 at a concentration of 1 lM, which is maximal for
the eﬀect on p44/p42 phosphorylation, did not aﬀect either
the ADP:ATP or AMP:ATP ratio.4. Discussion
To our knowledge, the only previous report of an interaction
between the AMPK and MAP kinase pathways had been one
suggesting that activation of AMPK inhibits activation of Ras,
Raf-1 and Erk by IGF-1 [19]. We were therefore surprised to
ﬁnd that U0126 and PD98059 caused a large activation of
AMPK that was associated with increased phosphorylation
of the activating phosphorylation site, Thr-172, and increased
phosphorylation of the downstream target, ACC-1. However,
the results in this paper show that this eﬀect is not mediated via
inhibition of MAP kinase, but instead appears to be a non-spe-
ciﬁc eﬀect on cellular energy status. Firstly, the concentrations
of U0126 and PD98059 required to cause AMPK activation
were higher than the concentrations required to inhibit p44/
p42 phosphorylation, particularly for U0126. Secondly, the
newer and more potent inhibitor PD184532 had no eﬀect of
AMPK activation at concentrations where its eﬀects on the
MAP kinase pathway were maximal. Finally, at concentra-
tions where they activate AMPK, U0126 and PD98059 (but
not PD184532) caused signiﬁcant increases in the cellular AD-
P:ATP and AMP:ADP ratios, indicating that they activate
AMPK by disturbing the levels of cellular nucleotides. Fig. 2
shows that the eﬀects of U0126 require the expression in the
cells of an active form of the upstream kinase, LKB1. This is
not unexpected because the major eﬀect of AMP on the AMPK
system is to promote phosphorylation by the upstream kinase.
Other drugs such as AICA riboside, which is converted into an
AMP analogue inside the cell [20], or biguanides like metformin
and phenformin, which are inhibitors of complex I of the
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ratio [21,22], also only activate AMPK in cells expressing
LKB1 [8]. Interestingly, the eﬀects of U0126 and phenformin
were not additive (Fig. 2), consistent with the idea that both
agents activate AMPK by the same mechanism, i.e., by increas-
ing cellular AMP.
Although all contain two or more aromatic rings, U0126,
PD98059 or PD184532 do not bear any obvious structural
relationship, and it is a little surprising that two out of the
three should cause a depletion of cellular ATP and consequent
activation of AMPK. However, the ﬁnding that PD184532 did
not have this non-speciﬁc eﬀect may be connected with the fact
that it is the most potent MAP kinase pathway inhibitor of the
three and was used at lower concentrations. It remains unclear
why U0126 and PD98059 cause elevation of ADP and AMP,
although inhibition of the mitochondrial respiratory chain,
coupled with the action of adenylate kinase to generate
AMP, would be one likely explanation.
Our results with PD184532 clearly indicate that the MAP ki-
nase pathway can be manipulated without consequent down-
stream eﬀects on the AMPK pathway. They do not refute
the proposal made by others for the reverse process, i.e., that
activation of AMPK inhibits activation of MAP kinase by
IGF-1, i.e., that MAP kinase lies downstream of AMPK [19].
Finally, our results show that great caution should be
exercised in interpretation of results obtained using U0126
and PD98059. At concentrations that are typically used in
the literature, these compounds activate AMPK and also
cause a disturbance in cellular nucleotides, which might have
secondary eﬀects unrelated to AMPK activation. This is a
particularly important issue in studies involving processes
that are known to be regulated by AMPK, such as glucose
transport. For example, PD98059 (50 lM) and U0126 (25
lM) were recently reported to inhibit insulin-stimulated 2-
deoxyglucose uptake in 3T3-L1 adipocytes, leading to the
proposal that MKK1/MEK has a role in activation of
GLUT4 [23]. However, our present studies show that these
concentrations of the inhibitors produce signiﬁcant activa-
tion of AMPK in HEK293 cells. It is already known that
activation of AMPK using AICA riboside inhibits insulin-
stimulated 2-deoxyglucose uptake in 3T3-L1 cells [24], so
the eﬀect of PD98059 and U0126 on this parameter [23]
may be due to AMPK activation and not to inhibition of
MKK1/MEK activation.
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